A 75-year-old man was admitted to the hospital with a loss of consciousness. His blood glucose level was 24 mg/dL. Abdominal computed tomography revealed multiple metastatic lesions in the liver, while upper endoscopy disclosed advanced gastric cancer. The hypoglycemia was refractory despite the administration of glucose and steroid therapy. The patient died within one month of admission. An autopsy revealed neuroendocrine-type gastric cancer, which, on examination with immunohistochemistry, was found to be negative for insulin and insulin-like growth factor I and positive for insulin-like growth factor II (IGF-II). The patient was diagnosed as having gastric cancer with non-islet cell tumor hypoglycemia (NICTH) caused by IGF-II.
Introduction
Hypoglycemia is one of the most common endocrine emergencies, estimated to occur in 0.9% of all hospitalized patients. In most cases, the hypoglycemia is related to the treatment of diabetes and endocrine deficiencies (1) . However, there are also reported cases of non-islet cell tumor hypoglycemia (NICTH) as a rare cause of hypoglycemia, which is generally associated with large, slow-growing, mesenchymal tumors arising from the retroperitoneum or the thorax (2) . Hypoglycemia associated with gastric cancer has rarely been reported (3) (4) (5) (6) ; however, its clinical manifestations remain to be explored. We herein report the case of a patient with gastric cancer with multiple liver metastases who presented with severe hypoglycemia in which an immunohistochemical analysis confirmed the expression of insulin-like growth factor II (IGF-II) in gastric cancer cells.
Case Report
A 75-year-old man with a two-month history of epigastric discomfort was admitted emergently to the Omori Red Cross Hospital with loss of consciousness. The initial Glasgow Coma Scale assessment revealed scores of E3, M4 and V3. On admission, the blood glucose level was found to be in the range of severe hypoglycemia (24 mg/dL). Abdominal computed tomography revealed multiple metastatic tumors in the liver and thickening of the stomach wall with no lesions detected in the pancreas or other organs (Fig. 1) . Upper gastrointestinal endoscopy revealed a large, hemorrhagic, protruberant tumor in the pylorus of the stomach (Fig. 2) , and a gastric biopsy revealed poorly differentiated adenocarcinoma. Therefore, the patient was diagnosed to have advanced gastric cancer with multiple liver metastases. On admission, the blood sodium level was 139 mEq/L (normal: mal: 95-105). The blood hemoglobin A1c level was normal at 5.0%. The levels of serum alpha-fetoprotein (AFP) and carcinoembryonic antigen (CEA) were elevated to 36.7 ng/ mL (normal: <10) and 41.6 mg/dL (normal: <5), respectively, whereas the serum carbohydrate antigen (CA 19-9) level was within the normal limits. The levels of tumor markers were as follows: An endocrinological examination revealed a reduced level of plasma insulin below 0.30 μIU/ mL (normal: 1.84-12 μIU/mL) and a plasma C-peptide level of 0.12 ng/mL (normal: 0.61-2.00 ng/mL). The plasma growth hormone level was 0.28 ng/mL (normal: below 0.17 ng/mL). The results of tests for anti-human insulin antibodies were negative. The blood cortisol and ACTH levels were within their normal ranges. The patient's thyroid function was normal. The serum level of insulin-like growth factor-I (IGF-I) was decreased to 10 ng/mL (normal: 73-311 ng/ mL). Because the blood insulin and C-peptide levels were suppressed during the hypoglycemic episode, we diagnosed the patient as having NICTH associated with gastric cancer. The hypoglycemia was refractory despite the administration of glucose at a high concentration in addition to steroid therapy. Chemotherapy to control the gastric cancer was initiated; however, the patient died of bronchopneumonia within one month after admission.
On autopsy, the gastric tumor exhibited a hemorrhagic surface and measured 7×6 cm in size. The tumor was histopathologically composed of relatively small atypical cells exhibiting small microtubular structures and small solid nests invading the fibrous interstitium. The tumor cells extended to the subserosal layer and the duodenum. Metastatic lesions were found within the liver and lymph nodes around the stomach. Using paraffin-embedded gastric and liver tissues, immunohistochemistry was performed with mouse monoclonal anti-synaptophysin antibodies (DakoCytomation, Carpinteria, CA, USA), rabbit polyclonal anti-chromogranin A antibodies (DakoCytomation) and rabbit polyclonal anti-IGF-II antibodies (Abcam, Tokyo, Japan). The tumor cells were strongly positive for synaptophysin, chromogranin A and IGF-II (Fig. 3) . The histopathological findings of the metastatic lesions of the liver were similar to those of the gastric tumor. Based on these findings, the gastric tumor was considered to be a neuroendocrine carcinoma (NEC) expressing IGF-II, thereby causing NICTH.
Discussion
Tumor-associated hypoglycemia is well known to be associated with the secretion of IGF-II (molecular weight: 7.5 kDa) (7, 8) . Structurally, IGF-II exhibits a high degree of homology to proinsulin. In normal serum, IGF-II exists in three different forms: free IGF-II, accounting for less than 1% and having a short half-life of approximately 10 minutes, bound IGF-II, accounting for 20-30% of total IGF-II and it is bound to 50-kDa IGFBPs, with a half-life of approximately 30 minutes, and a ternary 150-kDa complex, accounting for 70-80% of the total IGF-II, with a half-life of 12 hours. Not all tumors that overexpress the IGF-II gene cause NICTH; however, most cases of NICTH are caused by tumors. It is not clear whether the serum pro-IGF-II levels in patients with these tumors are already elevated prior to the appearance of the first signs of hypoglycemia (1) . In our present case, the patient was diagnosed as having hypoglycemic coma on admission with no previous history of diabetes. Due to the presence of upper abdominal symptoms (epigastric discomfort lasting for two months), we conducted gastrointestinal endoscopy and diagnosed the gastric tumor.
In patients with NICTH, serum IGF-II usually occurs in the high-molecular-weight form with a high proportion (usually >60%) of IGF-II being non-glycosylated and consisting primarily of IGF-II with a 21-amino acid extension of the E-domain [pro-IGF-IIE (66-88); 'big'-IGF-II] (7, 9, 10). 'Big'-IGF-II is biologically active and present in relatively high amounts in the sera of patients with NICTH. In most previously reported cases of NICTH, no elevations in the serum levels of total IGF-II were observed. Therefore, 'big'-IGF-II is considered to have specific biochemical properties and is different from mature IGF-II, resulting in enhancement of its bioavailability and consequent increases in its insulin-like activity in the body (11, 12) . Since 'big'-IGF-II fails to form the normal ternary 150-kDa complex and instead forms binary complexes, it can easily pass into the capillaries and deliver IGF-II to target organs of insulin, consequently inhibiting hepatic gluconeogenesis and increasing glucose uptake in skeletal tissue (13, 14) .
In the present case, immunohistochemistry demonstrated a positive reaction for IGF-II in the cancer cells in the stomach and liver. The anti-IGF II antibody used for the test in this case was a rabbit polyclonal antibody that is not specific to 'big'-IGF-II proteins. However, considering the positivity of the tumor cells for IGF II antibodies, as well as the existence of hypoglycemia on admission, the hypoglycemia observed in the present case is suggested to be associated with the expression of 'big'-IGF-II in the cancer cells, although we did not detect 'big'-IGF-II in the serum using a Western immunoblot analysis.
Neuroendocrine carcinoma (NEC) of the stomach is rare; however, particular attention must be paid to this tumor due to its aggressiveness and poor prognosis. Furthermore, liver metastasis is also closely related to the development of hypoglycemia in patients with gastric cancer. Marked hepatic structural destruction may further worsen hypoglycemia by blocking compensatory mechanisms that stimulate glycogenolysis in the liver. Therefore, overproduction of 'big'-IGF-II by tumors in combination with decreased hepatic glucose output associated with the destruction of hepatic tissue by tumor metastasis play a role in the onset of hypoglycemia in patients with liver metastasis. In addition, in this case, abdominal computed tomography performed on admission revealed multiple tumor metastases.
IGF-II is involved in fetal development, cell proliferation and apoptosis (15) (16) (17) , and overproduction of IGF-II plays a role in the facilitation of tumor growth (18) . In addition, an increased expression of IGF-II mRNA has been noted in human gastric cancer tissue, especially in infiltrative types of cancer with lymphatic invasion (19) . Therefore, abnormal imprinting of the IGF-II region may be related to rapid tumor metastasis as well as IGF-II production.
de Groot et al. reported that NICTH can arise in virtually every benign or malignant tumor and that 8% of cases of NICTH occur in the stomach (12) . According to a search of the MEDLINE database up to December 2012 using the terms "non-islet cell tumor hypoglycemia" and "gastric neuroendocrine carcinoma" and a search of the reference lists of published articles, there are no case reports describing gastric neuroendocrine carcinoma exhibiting NICTH. Therefore, we herein reported the first case of gastric neuroendocrine carcinoma that developed into NICTH.
In summary, we encountered a case of NICTH in a patient with gastric cancer associated with multiple liver metastases. Gastric cancer associated with NICTH caused by enhanced production of IGF-II is a rare, but important condition for medical physicians.
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